<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525499</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-J9-201</org_study_id>
    <nct_id>NCT00525499</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Dose-Ranging Clinical Study to Evaluate the Safety and Efficacy of ASC-J9 Cream Applied Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AndroScience Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AndroScience Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating
      acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with acne were randomized to one of four treatment groups for twice daily topical
      dosing to the face for 12 weeks. Assessments of acne status were performed at Baseline, Weeks
      2, 4, 8 and 12 and then 4 weeks after the last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Inflammatory Acne Lesion Counts From Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent change in inflammatory lesion counts from Baseline to Week 12. It is calculated by taking the Week 12 count minus the Baseline count and then dividing by the Baseline count. Thus, a negative percent change will reflect a reduction in lesion counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Investigator Global Assessment by at Least One Grade From Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Investigator Global Assessment used a static categorical scale, with zero corresponding to no acne and higher scores reflecting more severe acne:
0 No acne lesions.
Rare non-inflammatory lesions.
Some non-inflammatory lesions, no more than a few inflammatory lesions. No nodulo-cystic lesions.
Many non-inflammatory lesions, some inflammatory lesions, no more than one nodulo-cystic lesion.
Many noninflammatory and inflammatory lesions but no more than a few nodulo-cystic lesions.
Highly inflammatory lesions, multiple nodulo-cystic lesions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle control cream applied topically to the face twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC-J9 cream</intervention_name>
    <description>Topical application to the face twice daily for 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>vehicle control applied topically twice daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Androgen receptor degradation enhancer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 12 years of age.

          -  Facial acne, with:

             20 -100 inflammatory facial lesions 20 -100 noninflammatory facial lesions No more
             than 2 nodules/cysts on the face

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Skin diseases other than acne vulgaris

          -  Use of oral retinoids within 6 months of Baseline Visit

          -  Unwilling to discontinue all other treatments for facial acne

          -  Unwilling to avoid excessive swimming/sun exposure and use of cosmetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles CY Shih, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AndroScience Corp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>East Bay Dermatology Medical Group</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trial</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TKL Research, Inc</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Education and Research Foundation</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <results_first_submitted>January 31, 2011</results_first_submitted>
  <results_first_submitted_qc>March 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2011</results_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vehicle Control</title>
          <description>Vehicle control cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>0.001% ASC-J9 Cream</title>
          <description>0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>0.005% ASC-J9 Cream</title>
          <description>0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>0.025% ASC-J9 Cream</title>
          <description>0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle Control</title>
          <description>Vehicle control cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>0.001% ASC-J9 Cream</title>
          <description>0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>0.005% ASC-J9 Cream</title>
          <description>0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>0.025% ASC-J9 Cream</title>
          <description>0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="46"/>
            <count group_id="B5" value="186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" spread="4.9"/>
                    <measurement group_id="B2" value="18.0" spread="4.9"/>
                    <measurement group_id="B3" value="17.7" spread="5.8"/>
                    <measurement group_id="B4" value="18.3" spread="5.3"/>
                    <measurement group_id="B5" value="17.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Inflammatory Acne Lesion Counts From Baseline to Week 12</title>
        <description>Percent change in inflammatory lesion counts from Baseline to Week 12. It is calculated by taking the Week 12 count minus the Baseline count and then dividing by the Baseline count. Thus, a negative percent change will reflect a reduction in lesion counts.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT population: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Control</title>
            <description>Vehicle control cream applied topically to the face twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.001% ASC-J9 Cream</title>
            <description>0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.005% ASC-J9 Cream</title>
            <description>0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.025% ASC-J9 Cream</title>
            <description>0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inflammatory Acne Lesion Counts From Baseline to Week 12</title>
          <description>Percent change in inflammatory lesion counts from Baseline to Week 12. It is calculated by taking the Week 12 count minus the Baseline count and then dividing by the Baseline count. Thus, a negative percent change will reflect a reduction in lesion counts.</description>
          <population>ITT population: All randomized subjects</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.4" spread="41.0"/>
                    <measurement group_id="O2" value="-34.7" spread="32.4"/>
                    <measurement group_id="O3" value="-30.7" spread="47.6"/>
                    <measurement group_id="O4" value="-44.8" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Investigator Global Assessment by at Least One Grade From Baseline to Week 12</title>
        <description>The Investigator Global Assessment used a static categorical scale, with zero corresponding to no acne and higher scores reflecting more severe acne:
0 No acne lesions.
Rare non-inflammatory lesions.
Some non-inflammatory lesions, no more than a few inflammatory lesions. No nodulo-cystic lesions.
Many non-inflammatory lesions, some inflammatory lesions, no more than one nodulo-cystic lesion.
Many noninflammatory and inflammatory lesions but no more than a few nodulo-cystic lesions.
Highly inflammatory lesions, multiple nodulo-cystic lesions.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT population: All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Control</title>
            <description>Vehicle control cream applied topically to the face twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>0.001% ASC-J9 Cream</title>
            <description>0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>0.005% ASC-J9 Cream</title>
            <description>0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.025% ASC-J9 Cream</title>
            <description>0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Investigator Global Assessment by at Least One Grade From Baseline to Week 12</title>
          <description>The Investigator Global Assessment used a static categorical scale, with zero corresponding to no acne and higher scores reflecting more severe acne:
0 No acne lesions.
Rare non-inflammatory lesions.
Some non-inflammatory lesions, no more than a few inflammatory lesions. No nodulo-cystic lesions.
Many non-inflammatory lesions, some inflammatory lesions, no more than one nodulo-cystic lesion.
Many noninflammatory and inflammatory lesions but no more than a few nodulo-cystic lesions.
Highly inflammatory lesions, multiple nodulo-cystic lesions.</description>
          <population>ITT population: All randomized subjects</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vehicle Control</title>
          <description>Vehicle control cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>0.001% ASC-J9 Cream</title>
          <description>0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>0.005% ASC-J9 Cream</title>
          <description>0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>0.025% ASC-J9 Cream</title>
          <description>0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles CY Shih, PhD</name_or_title>
      <organization>AndroScience Corp</organization>
      <phone>(858) 638-7230</phone>
      <email>cyshih@androscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

